Compare GSK plc (GSK) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs 22nd Century Group Inc — how do they compare? GSK plc trades at $50.44 (market cap $101.13B), while 22nd Century Group Inc trades at $3.91 (market cap $1.49M). The key difference: GSK plc is far larger — about 67872.5× 22nd Century Group Inc's market cap, and GSK plc pays a 3.61% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals.
| GSK | XXII | |
|---|---|---|
Market Cap | $101.13B | $1.49M |
Sector | Health | Technology |
52-Week High | $61.18 | $801.00 |
52-Week Low | $38.96 | $3.72 |
Enterprise Value | $121.57B | -$6.74M |
Dividend Yield | 3.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
22nd Century Group (XXII) trades at $4.31, down 0.92% on the day, with a neutral technical signal and bearish moving averages. The company shows deep unprofitability with a gross margin of -52.19% and net margin of -65.76%, though revenue was $7.05M in 2025. Recent corporate actions include a 20:1 reverse stock split in June 2026, and news highlights retail expansion for VLN reduced-nicotine cigarettes in California and New York.
The outlook remains speculative with high execution risk amid persistent losses, but analyst sentiment is bullish with 75% buy ratings. Key risks include negative cash flow from operations, regulatory hurdles for tobacco products, and the need for successful commercialization of VLN to achieve profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
